A detailed history of American Portfolios Advisors transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, American Portfolios Advisors holds 4,619 shares of NBIX stock, worth $531,785. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,619
Holding current value
$531,785
% of portfolio
0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$92.03 - $107.81 $425,086 - $497,974
4,619 New
4,619 $491 Million
Q2 2022

Mar 20, 2023

BUY
$75.79 - $100.07 $7,275 - $9,606
96 Added 2.08%
4,715 $460 Million
Q1 2022

Mar 21, 2023

BUY
$72.45 - $94.81 $20,141 - $26,357
278 Added 6.02%
4,897 $459 Million
Q4 2021

Mar 21, 2023

SELL
$79.65 - $106.22 $202,629 - $270,223
-2,544 Reduced 55.08%
2,075 $177 Million
Q3 2021

Mar 22, 2023

SELL
$86.18 - $99.03 $231,996 - $266,588
-2,692 Reduced 58.28%
1,927 $185 Million
Q2 2021

Mar 22, 2023

SELL
$89.43 - $102.27 $241,461 - $276,129
-2,700 Reduced 58.45%
1,919 $187 Million
Q1 2021

Mar 22, 2023

SELL
$87.57 - $119.4 $201,060 - $274,142
-2,296 Reduced 49.71%
2,323 $226 Million
Q4 2020

Mar 22, 2023

SELL
$86.91 - $108.33 $202,152 - $251,975
-2,326 Reduced 50.36%
2,293 $220 Million
Q3 2020

Mar 22, 2023

SELL
$96.16 - $135.15 $227,322 - $319,494
-2,364 Reduced 51.18%
2,255 $217 Million
Q2 2020

Mar 24, 2023

SELL
$85.09 - $130.36 $1,531 - $2,346
-18 Reduced 3.54%
490 $59.8 Million
Q1 2020

Mar 24, 2023

SELL
$75.11 - $113.76 $308,777 - $467,667
-4,111 Reduced 89.0%
508 $44 Million
Q4 2019

Mar 24, 2023

SELL
$86.8 - $118.57 $333,312 - $455,308
-3,840 Reduced 83.13%
779 $83.7 Million
Q3 2019

Mar 24, 2023

SELL
$83.82 - $101.5 $3,604 - $4,364
-43 Reduced 5.82%
696 $62.7 Million
Q2 2019

Mar 24, 2023

SELL
$72.24 - $91.27 $280,291 - $354,127
-3,880 Reduced 84.0%
739 $62.4 Million
Q3 2018

Mar 24, 2023

SELL
$98.88 - $125.85 $422,118 - $537,253
-4,269 Reduced 92.42%
350 $43 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.